Aesyra has raised $3 million in a financing round led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher Kantonalbank.
About the funding
The new financing will support the development and commercialization of Aesyra’s AesyBite™ line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea. Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide. A spin-off of the Federal Institute of Technology of Lausanne (EPFL) in Switzerland, Aesyra has pioneered a powerful technology system — that combines a unique oral appliance device and proprietary sensors — that has demonstrated over 70% reduction of bruxism activity for users. Powering Aesyra’s AesyBite™ are technologies and algorithms that leverage over years of sleep research data.
“This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”
“Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea,” said Michael Masterson, Managing Partner at Supermoon Capital “We are impressed by the company’s unique approach, strong leadership team and unwavering commitment to revolutionize healthcare, and we are looking forward to working closely with Aesyra to support its mission.”
“We selected Aesyra as the first investment of Creadd Ventures since it perfectly fits our philosophy to invest in companies that have the potential to make a profound impact on the quality of life of patients,” said Lorenzo Leoni, Founder and Managing Partner at Creadd Ventures.
Masterson and Leoni will join the Board of Directors of Aesyra, bringing their extensive industry expertise and strategic guidance to accelerate the company’s growth and success.
About Supermoon Capital
Supermoon Capital is the only venture capital firm in the world focused exclusively on the sleep technology market. The San Francisco-based firm partners with visionary innovators across the sleep market spectrum encompassing chronobiology, neurotech, biotech, pharmaceuticals, medtech, consumer interventions, and enterprise solutions. Supermoon and its global network of prominent academics, strategic partners, and renowned sleep scientists support companies across a range of functions, including product development, go-to-market strategy, and growth financing. For more information, please visit www.supermooncapital.com.
Creadd Ventures is a new venture capital fund with a focus on investing Biomedical, DeepTech and SAAS companies based in Switzerland and Europe. The fund’s investment strategy involves targeting emerging early-stage companies with strong management teams, a solid and proprietary scientific foundation, and a clear go to market strategy. Creadd leverages the extensive experience and network of both founding partners as entrepreneurs and fund managers. For more information, please visit www.creadd.ch.